Skip to main content
SpringerLink
Log in

Traditional Management of Liver Disorders

  • Published:
Drugs Aims and scope Submit manuscript

An Erratum to this article was published on 01 May 1992

Summary

Dietary measures have achieved mixed results in the management of liver disorders. Although a high energy diet may shorten the course of viral hepatitis by a relatively small amount, dietary restriction is usually of no benefit in compensated cirrhosis. Restriction of sodium intake to 22 to 60 mol/day leads to resolution of cirrhotic ascites in approximately 20% of patients, and reduces the requirement for diuretics in the remainder. In advanced liver disease, diet plays an important role in the avoidance of portal-systemic encephalopathy (PSE), with the tolerance of most nutrients, most importantly protein, being sharply reduced. Despite the frequent presence of carbohydrate intolerance in liver disease, carbohydrate supplementation may be required to ensure adequate utilisation of the reduced dietary protein intake. Zinc supplementation may also be required in liver cirrhosis to compensate for a deficiency.

Bed rest is an important component of the management of acute and chronic liver disorders, together with the avoidance of fatigue. Abstinence from alcohol is required in alcoholic liver disease patients, who should receive parenteral thiamine 100mg and other vitamin and mineral supplementation as required.

Agents acting on the ascending loop of Henle [such as furosemide (frusemide)] or the distal tubule (such as spironolactone) are the diuretics most frequently employed to mobilise ascites in cirrhosis, the latter drug being the more effective in nonazotaemic patients. In the absence of oedema, the diuresis should be restricted to a maximum of 750 ml/day; however, patients with oedema may safely undergo a diuresis of ⩽ 1.5 L/day. Diuretic therapy is often associated with renal complications, such as azotaemia (usually reversible) and severe hyponatraemia in cirrhotic patients with ascites; spironolactone may produce antiandrogenic adverse effects.

Lactulose, used in the treatment of acute and chronic PSE, acts by inhibiting gastrointestinal absorption of ammonia and other toxic nitrogenous substances, and by reducing urea degradation. Other pharmacological treatments, such as branched-chain amino acids and benzodiazepine antagonists have a limited role in the management of PSE. Chronic cholestasis has been treated with cholestyramine and fat-soluble vitamins, whereas ursodeoxycholic acid appears to be a promising agent in the treatment of primary biliary cirrhosis. In chronic hepatitis, the prevention of development of cirrhosis is a primary treatment goal which has been attempted with variable success using antifibrotic drugs such as penicillamine and colchicine.

Corticosteroids such as prednisolone are of benefit in severe autoimmune chronic active hepatitis, and azathioprine has proven to be useful adjunctive therapy. The lowest effective dose should be used during long term administration of steroids; a trial withdrawal may be successful after 1 to 2 years. Preliminary data only are available concerning the use of other immunosuppressive drug groups in primary biliary cirrhosis. Vaccination against hepatitis B virus with plasma-derived or recombinant products has been very successful and is an effective means of protecting high-risk populations. Antithyroid treatment using propylthiouracil can reduce the mortality associated with alcoholic liver disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alberti A, Cavaletto D, Pontisso P. Antibody response to pre-S2 and hepatitis virus induced liver damage. Lancet 1: 1421–1424, 1988

    PubMed  CAS  Google Scholar 

  • Andre F, Safary A. Clinical experience with a yeast derived hepatitis B vaccine. In Zuckerman A (Ed.) Viral hepatitis and liver disease, pp. 1025–1030, Alan R Liss Inc., New York, 1988

    Google Scholar 

  • Arnold W, Baumann W. Vaccination of children with malignant diseases with alum-absorbed hepatitis B vaccine-immunogenicity studies. Scandinavian Journal of Infectious Diseases (Suppl. 38): 33–36, 1983

    Google Scholar 

  • Arroyo V, Rodes J. A rational approach to the treatment of ascites. Postgraduate Medicine 51: 558–562, 1975

    CAS  Google Scholar 

  • Arroyo V, Gines P, Planas R, Panes J, Rodes J. Management of patients with cirrhosis and ascites. Seminars in Liver Disease 6: 353–369, 1986

    PubMed  CAS  Google Scholar 

  • Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled double-blind clinical trial. Digestive Diseases and Sciences 23: 398–406, 1978

    CAS  Google Scholar 

  • Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 2: 1099–1102, 1983

    PubMed  CAS  Google Scholar 

  • Bernardi M, Santini C, Trevisani F, et al. Renal function impairment induced by change in posture in patients with cirrhosis and ascites. Gut 26: 629–635, 1985

    PubMed  CAS  Google Scholar 

  • Bircher J, Muller J, Guggenheim P, et al. Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet 1: 890–892, 1966

    PubMed  CAS  Google Scholar 

  • Bodenheimer HJ, Schaffner F, Pezzulo J. Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology 95: 124–129, 1988

    PubMed  Google Scholar 

  • Brissot P, Le Treut A, Dien G, et al. Hypovitaminemia A in idiopathic hemochromatosis and hepatic cirrhosis. Digestion 17: 469–478, 1978

    PubMed  CAS  Google Scholar 

  • Brunt PW, Ken MC, Scheuer PJ, Sherlock S. Studies in alcoholic liver disease in Britain. I. Clinical and pathological patterns related to natural history. Gut 15: 52–58, 1974

    PubMed  CAS  Google Scholar 

  • Cerra FB, Cheung NK, Fischer JE, et al. Disease-specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double-blind controlled trial. Journal of Parenteral and Enteral Nutrition 9: 288–295, 1985

    PubMed  CAS  Google Scholar 

  • Chalmers TC, Eckhardt RD, Reynolds WE, Cigarroa JG, Deane N, et al. The treatment of acute infectious hepatitis: studies of the effect of diet, rest and physical reconditioning on the acute course of the disease and on the incidence of relapse and residual abnormalities. Journal of Clinical Investigation 34: 1163–1235, 1955

    PubMed  CAS  Google Scholar 

  • Coates RA, Halliday ML, Rankin JG. Immunogenicity and safety of a yeast derived recombinant DNA hepatitis B vaccine in health care workers. In Zuckerman A (Ed.) Viral hepatitis and liver disease, pp. 1038–1046, Alan R Liss Inc., New York, 1988

    Google Scholar 

  • Conn HO, Leevy CM, Vlachevic ZR, Rodgers JB, Maddrey WC, et al. A comparison of lactulose and neomycin in the treatment of portal-systemic encephalopathy: a double-blind controlled trial. Gastroenterology 72: 573–583, 1977

    PubMed  CAS  Google Scholar 

  • Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Quarterly Journal of Medicine 40: 159–185, 1971

    PubMed  CAS  Google Scholar 

  • Coursaget P, Yvonnet B, Anthonioz P. Immunogenicity of an hepatitis B vaccine obtained by genetic recombination and containing S and pre S2 genes products. Presse Médicale 17: 1150–1151, 1988

    CAS  Google Scholar 

  • Cronin RE, Knochel JP. Magnesium deficiency. Advances in Internal Medicine 28: 509–533, 1983

    PubMed  CAS  Google Scholar 

  • Crosnier J, Jungers P, Courouce AM, et al. Randomized placebo-controlled trials of hepatitis B surface antigen vaccine in French hemodialysis units. I. Medical staff. Lancet 1: 455–459, 1981

    PubMed  CAS  Google Scholar 

  • Crowe J, Christensen E, Smith M, et al. Azathioprine in primary biliary cirrhosis: a report of an international trial. Gastroenterology 78: 1005–1010, 1980

    PubMed  CAS  Google Scholar 

  • Czaja AJ, Ludwig J, Baggenstoss AH, et al. Corticosteroid treated chronic hepatitis. New England Journal of Medicine 304: 5–9, 1981

    PubMed  CAS  Google Scholar 

  • Czaja AJ, Davis OL, Ludwig J, et al. Auto-immune features as determinants of prognosis in steroid treated chronic active hepatitis of uncertain etiology. Gastroenterology 85: 713–717, 1983

    PubMed  CAS  Google Scholar 

  • Datta DV, Sherlock S. Treatment of pruritus of obstructive jaundice with cholestyramine. British Medical Journal 1: 216–219, 1963

    PubMed  CAS  Google Scholar 

  • Dawson AM, Mc Clarent J, Sherlock S. Neomycin in the treatment of hepatic coma. Lancet 2: 1263–1268, 1957

    Google Scholar 

  • Dienstag JL, Stevens CE, Bhan AK, et al. Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen. Annals of Internal Medicine 96: 575–579, 1982

    PubMed  CAS  Google Scholar 

  • Egberts EH, Schomerus H, Hamster W, Jurgens P. Effective treatment of latent portosystemic encephalopathy with oral branched-chain amino-acids. In Capocaccia L el al. (Ed.) Hepatic encephalopathy in chronic liver disease, pp. 351–357, Plenum Press, New York, 1984

    Google Scholar 

  • Egberts EH, Schomerus H, Hamster W. et al. Branched chain amino-acids in the treatment of latent porto-systemic encephalopathy. A double-blind placebo cross-over study. Gastroenterology 88: 887–895, 1985

    PubMed  CAS  Google Scholar 

  • Elkington SG, Floch MH, Conn HO. Lactulose in the treatment of chronic portal-systemic encephalopathy: a double-blind clinical trial. New England Journal of Medicine 281: 408–412, 1969

    PubMed  CAS  Google Scholar 

  • Epstein O, Jain S, Lee RG, et al. D-penicillamine treatment improves survival in primary biliary cirrhosis. Lancet 1: 1275–1277, 1981

    PubMed  CAS  Google Scholar 

  • Eriksson LS. Branched-chain amino-acids in the treatment of hepatic encephalopathy. In Conn HO, Bircher J (Eds) Hepatic encephalopathy: management with lactulose and related carbohydrates, pp. 129–141, Medi-Ed Press, East Lansing, Michigan, 1988

    Google Scholar 

  • Eriksson LS, Person A, Warhren J. Branched-chain amino-acids in the treatment of chronic hepatic encephalopathy. Gut 23: 801–806, 1982

    PubMed  CAS  Google Scholar 

  • Fagan EA, Tolley P, Smith HM, et al. Hepatitis B vaccine: follow-up including two-year booster doses in high-risk health care personnel in a London teaching hospital. Journal of Medicine Virology 21: 49–56, 1987

    CAS  Google Scholar 

  • Fcnton JCB, Knight EJ, Humpherson PL. Milk and cheese diet in portal systemic encephalopathy. Lancet 1: 164–166, 1966

    Google Scholar 

  • Ferenci P, Dragosics B, Dittrich H. Randomized controlled trial of Silymarin treatment in patients with cirrhosis of the liver. Journal of Hepatology 9: 105–113, 1989

    PubMed  CAS  Google Scholar 

  • Fiaccadori F, Ginelli F, Pedretti G, et al. Branched-chain enriched amino acid solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology 17: 5–10, 1985

    Google Scholar 

  • Fischer JE, Baldassarini RJ. False neurotransmitters and hepatic failure. Lancet 2: 75–79, 1971

    PubMed  CAS  Google Scholar 

  • Fischer JE, Baldassarini RJ. Pathogenesis and therapy of hepatic coma. In Popper H, Schaffner F (Eds) Progress in liver disease, vol. V, pp. 363–397, Grune and Stratton, New York, 1976

    Google Scholar 

  • Francis DP, Hadler JC, Thompson SE, et al. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Annals of Internal medicine 97: 362–366, 1982

    PubMed  CAS  Google Scholar 

  • Galambos JT. Alcoholic hepatitis. In Schaffner F, et al. (Eds) The liver and its diseases. Intercontinental medical book, pp. 255–267, New York, 1974

    Google Scholar 

  • Garcia-Compean D, Uribe M. Fiber rather than protein determines tolerance to nitrogen load in chronic portal systemic encephalopathy: a randomized trial. Hepatology 7: 1034, 1987

    Google Scholar 

  • Gauthier A, Levy VG, Quinton A, et al. Salt or not salt in the treatment of cirrhotic ascites: a randomised study. Gut 27: 705–709, 1986

    PubMed  CAS  Google Scholar 

  • Gerety RJ. Recombinant hepatitis B vaccines. In Zuckerman A (Ed.) Viral hepatitis and liver disease, pp. 1017–1024, Alan R Liss Inc., New York, 1988

    Google Scholar 

  • Greenberger NJ, Carley J, Schenker S, Bettinger I, Stammes C, et al. Effect of vegetable and animal protein diets in chronic encephalopathy. Digestive Diseases and Sciences 22: 845–855, 1977

    CAS  Google Scholar 

  • Grimm G, Ferenci P, Katzenschlager R, et al. Improvement of hepatic encephalopathy treated with flumazenil. Lancet 2: 1392–1394, 1988

    PubMed  CAS  Google Scholar 

  • Guarascio P, Portmann B, Visco G, et al. Liver damage with reversible portal hypertension from vitamin A intoxication: demonstration of Ito cells. Journal of Clinical Pathology 36: 769–771, 1983

    PubMed  CAS  Google Scholar 

  • Hahn M, Massen O, Nencki M, et al. Die Eck’sche fistelwischen der interen Hohlvene and der pfortader und ihre foigen fur denorganismes. Archiv für Experimentelle Pathologie und Pharmakologie 32: 161–210, 1893

    Google Scholar 

  • Halle P, Pare P, Kaptein E. Double-blind controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology 82: 925–931, 1982

    PubMed  CAS  Google Scholar 

  • Heathcote J, Ross A, Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 70: 656–660, 1976

    PubMed  CAS  Google Scholar 

  • Hegarty J, Nouri AK, Portmann B, et al. Relapse following treatment withdrawal in patients with auto-immune chronic active hepatitis. Hepatology 3: 685–689, 1983

    PubMed  CAS  Google Scholar 

  • Heredia D, Caballeria J, Arroyo V, Ravelli G, Rodes J. Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy. A controlled trial. Journal of Hepatology 4: 293–298, 1987

    PubMed  CAS  Google Scholar 

  • Herrman R, Shakor, Weber FL. Beneficial effect of pectin in chronic hepatic encephalopathy. Gastroenterology 92: 1795, 1987

    Google Scholar 

  • Hoofnagle J H, David GL, Schafer DF, et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 91: 1327–1334, 1986a

    PubMed  CAS  Google Scholar 

  • Hoofnagle J H, Davis GL, Pappas SC, et al. A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 104: 12–17, 1986b

    PubMed  CAS  Google Scholar 

  • Horst D, Grace ND, Conn HO, Atterbury CE. Comparison of dietary protein with oral branched-chain amino-acids in chronic portosystemic encephalopathy: a randomized controlled trial. Hepatology 4: 279–287, 1984

    PubMed  CAS  Google Scholar 

  • Iber FL, Rosen H, Levenson SM, et al. The plasma amino acids in patients with liver failure. Journal of Laboratory and Clinical Medicine 50: 417–425, 1957

    PubMed  CAS  Google Scholar 

  • Immunization Practices Advisory Committee (IPAC). Update on hepatitis B prevention. Annals of Internal Medicine 107: 353–357, 1987

    Google Scholar 

  • Israël Y, Videla L, Bernstein J. Liver hypermetabolic state after chronic ethanol consumption: hormonal interrelations and pathogenic implications. Federation Proceedings: Federation of American Societies for Experimental Biology 34: 2052–2059, 1975a

    Google Scholar 

  • Israël YT, Kalant H, Orrego H, et al. Experimental alcohol-induced hepatic necrosis: suppresssion by propylthiouracil. Proceedings of the National Academy of Sciences of the United States of America 72: 1137–1141, 1975b

    PubMed  Google Scholar 

  • Jilg W, Schmidt M, Deinhardt F. Persistence of specific antibodies after hepatits B vaccination. Journal of Hepatology 6: 201–207, 1988a

    PubMed  CAS  Google Scholar 

  • Jilg W, Schmidt M, Deinhardt F. Immune response to hepatitis B revaccination. Journal of Medical Virology 24: 377–384, 1988b

    PubMed  CAS  Google Scholar 

  • Jones CM. The evolution and treatment of late disease of the liver. Annals of Internal Medicine 33: 292–297, 1950

    PubMed  CAS  Google Scholar 

  • Kaplan MM. Medical treatment of primary biliary cirrhosis. Seminars in Liver Disease 9: 138–143, 1989

    PubMed  CAS  Google Scholar 

  • Kaplan MM, Alling DW, Wolfe HJ, et al. A prospective trial of colchicine for primary biliary cirrhosis. New England Journal of Medicine 315: 1448–1454, 1986

    PubMed  CAS  Google Scholar 

  • Kaplan MM, Knox TA, Arora S. Primary biliary cirrhosis treated with low-dose oral pulse methotrexate: resolution of symptoms with improvement in biochemical tests of liver function. Annals of Internal Medicine 109: 429–431, 1988

    PubMed  CAS  Google Scholar 

  • Keeling PWN, Ruse W, Bull J, Hannigan B, Thompson RPH. Direct measurement of the intestinal extraction of zinc in cirrhosis and hepatitis. Clinical Science 61: 441–444, 1981

    PubMed  CAS  Google Scholar 

  • Kershenobich D, Vargas F, Garcia-Tsao G, Tamayo RP, Gent M, et al. Colchicine in the treatment of cirrhosis of the liver. New England Journal of Medicine 318: 1709–1713, 1988

    PubMed  CAS  Google Scholar 

  • Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. New England Journal of Medicine 316: 1562–1568, 1987

    PubMed  CAS  Google Scholar 

  • Lam KC, Lai CL, Ng RP, et al. Deleterious effect of prednisolone in HBsAg positive chronic active hepatitis. New England Journal of Medicine 304: 380–386, 1981

    PubMed  CAS  Google Scholar 

  • Leaf A. The clinical and physiologic significance of the serum sodium concentration. New England Journal of Medicine 267: 77–84, 1962

    PubMed  CAS  Google Scholar 

  • Liskow BI, Goodwin DW. Pharmacological treatment of alcohol intoxication, withdrawal and dependence: a critical review. Journal of Studies on Alcohol 48: 356–370, 1987

    PubMed  CAS  Google Scholar 

  • Maier KP. Progress in the treatment of portal-systemic encephalopathy. Journal of Hepatology 5: 355–361, 1987

    PubMed  CAS  Google Scholar 

  • Meister A. New developments in glutathione metabolism and their potential application in therapy. Hepatology 4: 739–742, 1984

    PubMed  CAS  Google Scholar 

  • Merli M, Riggio O, Ipichino S, et al. Amino acid imbalance and malnutrition in liver cirrhosis. Human Nutrition — Clinical Nutrition 4: 249–253, 1985

    CAS  Google Scholar 

  • Michel H, Bories P, Aubin JP, et al. Treatment of acute hepatic encephalopathy in cirrhotics with a branched-chain amino acids enriched versus a conventional amino-acids mixture. A controlled study of 70 patients. Liver 5: 282–289, 1985

    PubMed  CAS  Google Scholar 

  • Milich DR, Thornton GB, Neurath AR. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 228: 1195–1199, 1985

    PubMed  CAS  Google Scholar 

  • Minuk G, Bohme C, Burgess E, et al. A prospective, double-blind, randomised, controlled trial of cyclosporin A in primary biliary cirrhosis. Hepatology 7: 1119, 1987

    Google Scholar 

  • Mitchison HC, Bassendine MF, Record CO, et al. Controlled trial of prednisolone for primary biliary cirrhosis: good for the liver, bad for bones? Hepatology 6: 1211, 1986

    Google Scholar 

  • Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. Gut 23: 1–7, 1982

    PubMed  CAS  Google Scholar 

  • Morgan MY, Hawley KE, Stambuk D. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study. Journal of Hepatology 4: 236–244, 1987

    PubMed  CAS  Google Scholar 

  • Morrison SA, Russel RM, Carney EA, Oaks EV. Zinc deficiency: a cause of abnormal dark adaptation in cirrhotics. American Journal of Clinical Nutrition 31: 276–281, 1978

    PubMed  CAS  Google Scholar 

  • Nair PU, Tong MJ, Stewenson D, et al. A pilot study on the effect of prednisone withdrawal on serum hepatitis B virus DNA and H Be Ag in chronic active hepatitis B. Hepatology 6: 1319–1324, 1986

    PubMed  CAS  Google Scholar 

  • Naranjo CA, Sellers EM, Chater K, et al. Nonpharmacologic intervention in acute alcohol withdrawal. Clinical Pharmacology and Therapeutics 34: 214–219, 1983

    PubMed  CAS  Google Scholar 

  • Omata M, Imazeki F, Yokosuka O, et al. Recombinant leukocyte A interferon treatment in patients with chronic hepatitis B virus infection. Gastroenterology 88: 870–880, 1985

    PubMed  CAS  Google Scholar 

  • Orrego H, Carmichael FJ, Phillips MJ. Protection by propylthiouracil against carbon tetrachloride-induced liver damage. Gastroenterology 71: 821–826, 1976

    PubMed  CAS  Google Scholar 

  • Orrego H, Kalant H, Israël Y. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology 76: 105–115, 1979

    PubMed  CAS  Google Scholar 

  • Orrego H, Blake JE, Blendis LM. Long-term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine 317: 1421–1427, 1987

    PubMed  CAS  Google Scholar 

  • Perez-Ayuso RM, Arroyo V, Camps J, et al. Effect of demeclo-cycline on renal function and urinary prostaglandin E2 and kallitrecin in hyponatremic cirrhotics. Nephron 36: 30–37, 1984a

    PubMed  CAS  Google Scholar 

  • Perez-Ayuso RM, Arroyo V, Planas R, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Gastroenterology 84: 961–968, 1984b

    Google Scholar 

  • Perrillo RP, Regenstein FG, Bodicky CJ, et al. Comparative efficacy of adenine arabinoside 5′ monophosphate and prednisone withdrawal followed by adenine arabinoside 5′ monophosphate in the treatment of chronic active hepatitis type B. Gastroenterology 88: 780–786, 1985

    PubMed  CAS  Google Scholar 

  • Perrillo RP, Regenstein FG, Eters MG, et al. Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized controlled trial. Annals of Internal Medicine 109: 95–100, 1988

    PubMed  CAS  Google Scholar 

  • Petrides AS, De Fronzo RA. Glucose and insulin metabolism in cirrhosis. Journal of Hepatology 8: 107–114, 1989

    PubMed  CAS  Google Scholar 

  • Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 90: 1827–1833, 1986

    PubMed  CAS  Google Scholar 

  • Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1: 834–836, 1987

    PubMed  CAS  Google Scholar 

  • Powel WJ, Klatskin G. Duration of survival in patients with Laennec’s cirrhosis. Influence of alcohol withdrawal and possible effects of recent changes in general management of the disease. American Journal of Medicine 44: 406–420, 1968

    Google Scholar 

  • Powell LW, Akelsen E. Corticosteroids in liver diseases: studies on the biologic conversion of prednisone to prednisolone and plasma protein binding. Gut 13: 690–696, 1972

    PubMed  CAS  Google Scholar 

  • Purcell RH, Gerin JL. Prospects for second and third generation hepatitis B vaccines. Hepatology 5: 159–163, 1985

    PubMed  CAS  Google Scholar 

  • Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves chronic hepatic encephalopathy. Results of a randomized controlled clinical trial. Lancet 2: 493–494, 1984

    PubMed  CAS  Google Scholar 

  • Reed JS, Liskow MD. Current medical treatment of alcohol withdrawal. Rational Drug Therapy 21: 1–6, 1987

    PubMed  CAS  Google Scholar 

  • Ritland S, Petlund CF, Knudsen T, Skrede S. Improvement of physical capacity after long-term training in patients with chronic active hepatitis. Scandinavian Journal of Gastroenterology 18: 1083–1097, 1983

    PubMed  CAS  Google Scholar 

  • Rodes J, Bosch J, Arroyo V. Clinical types and drug therapy of renal impairment in cirrhosis. Postgraduate Medical Journal 55: 492–497, 1975

    Google Scholar 

  • Rojkind M, Kershenovich D. Effect of colchicine on collagen, albumin and transferrin synthesis by cirrhotic rat liver slices. Biochimica et Biophysica Acta 378: 415–423, 1975

    PubMed  CAS  Google Scholar 

  • Rojkind M, Uribe M, Kershenobich D. Colchicine and the treatment of liver cirrhosis. Lancet 1: 38–39, 1973

    Google Scholar 

  • Rossi-Fanelli F, Riggio O, Cangiono C, et al. Branched chain amino acids vs lactulose in the treatment of hepatic coma. A controlled study. Digestive Diseases and Sciences 27: 929–935, 1982

    PubMed  CAS  Google Scholar 

  • Routhier G, Epstein O, Janossy G, Thomas HC, Sherlock S. The effects of cyclosporin A on suppression and inducer T-lymphocytes in primary biliary cirrhosis. Lancet 2: 1223–1226, 1980

    PubMed  CAS  Google Scholar 

  • Rudman D, Smith RB, Salam A, Warren WD, Galambos JT, et al. Ammonia content of food. American Journal of Clinical Nutrition 26: 487–490, 1970

    Google Scholar 

  • Salmi HA, Sarna S. Effect of Silymarin on chemical, functional and morphological alterations of the liver. Scandinavian Journal of Gastroenterology 17: 517–520, 1982

    PubMed  CAS  Google Scholar 

  • Sato Y, Eriksson S, Hagenfeldt L, et al. Influence of branched chain amino acid infusion on arterial concentrations and brain exchange of amino-acids in patients with hepatic cirrhosis. Clinical Physiology 1: 151–165, 1981

    Google Scholar 

  • Schaffner F. Management of chronic hepatitis. Seminars in liver disease 5: 209–220, 1985

    PubMed  CAS  Google Scholar 

  • Schaffner F, Klion FM, Latuff AJ. Long-term use of cholestyramine in the treatment of primary biliary cirrhosis. Gastroenterology 48: 293–298, 1965

    PubMed  CAS  Google Scholar 

  • Schaffner F, Bacchin PG, Hutterer F, et al. Mechanism of cholestasis. 4. Structural and biochemical changes in the liver and serum in rats after bile duct ligation. Gastroenterology 60: 888–897, 1971

    PubMed  CAS  Google Scholar 

  • Schimmelpfennig W, Wack R, Maluszek S, et al. Immunosuppressive Therapie der aktiven chronischen Hepatitis. Deutsche Gesundheit-Wesen 34: 298–301, 1979

    Google Scholar 

  • Schölmerich J, Becher MS, Schmidtk, et al. Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties. Studies on isolated hepatocytes and lipid membranes vesicles. Hepatology 4: 661–666, 1984

    PubMed  Google Scholar 

  • Schomerus H, Wiedmann KH, Dolle W. (+)-cyanidol-3 in the treatment of acute viral hepatitis: a randomized controlled trial. Hepatology 4: 331–335, 1984

    PubMed  CAS  Google Scholar 

  • Scrip 1033: 24, 1985

  • Scrip 1042: 23, 1985

  • Shaw S, Heller EA, Friedman HS. Increased hepatic oxygenation following ethanol administration in the baboon. Proceedings of the Society for Experimental Biology and Medicine 156: 509–513, 1977

    PubMed  CAS  Google Scholar 

  • Sherlock S. Ascites formation and its management. Scandinavian Journal of Gastroenterology 7 (Suppl.): 9–15, 1970

    CAS  Google Scholar 

  • Soeters P, Fischer JE. Insulin, glucagon, amino acid imbalance, and hepatic encephalopathy. Lancet 2: 880–882, 1976

    PubMed  CAS  Google Scholar 

  • Soloway RD, Summerskill WHJ, Baggenstoss AH, et al. Clinical, biochemical and histological remission of severe chronic active liver disease. A controlled study of treatments and early prognosis. Gastroenterology 63: 820–833, 1972

    PubMed  CAS  Google Scholar 

  • Stellon AJ, Keating JJ, Johnson PJ, et al. Maintenance of remission in auto-immune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 4: 781–784, 1988

    Google Scholar 

  • Stevens CE, Alter HJ, Taylor PE, et al. Hepatite B vaccine in patients receiving hemodialysis: immunogenicity and efficacy. New England Journal of Medicine 311: 496–501, 1984

    PubMed  CAS  Google Scholar 

  • Stevens CE, Taylor PE, Rubinstein P, et al. Safety of the hepatitis B vaccine. New England Journal of Medicine 312: 375–376, 1985

    PubMed  CAS  Google Scholar 

  • Summerskill WHJ, Korman MG, Ammon HV, et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 16: 876–883, 1975

    PubMed  CAS  Google Scholar 

  • Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. New England Journal of Medicine 303: 833–841, 1980

    PubMed  CAS  Google Scholar 

  • Thompson JS, Schafer DF, Maune J, et al. Adequate diet prevents hepatic coma in dogs with Eck’s fistula. Surgery, Gynecology and Obstetrics 162: 126–130, 1986

    PubMed  CAS  Google Scholar 

  • Trinchet JC, Bcaugrand M, Callard P, et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double trial. Gastroentérologie Clinique et Biologique 13: 551–555, 1989

    PubMed  CAS  Google Scholar 

  • Tron F, Degos F, Brechot C. Immunogenicity and safety of a new recombinant hepatitis B vaccine prepared in mammalian cell and containing pre S2 and S epitopes. Journal of Medical Virology 21: 105 A, 1987

    Google Scholar 

  • Tron F, Degos F, Brechot C. Randomised dose range study of a recombinant vaccine produced in mammalian cells containing the S and pre S sequences, in press

  • Uribe M. Dietary management of portal-systemic encephalopathy. In Conn HO, Bircher J (Eds) Hepatic encephalopathy — management with lactulose and related carbohydrates, chap. 8, pp. 95–112. Mcdi-Ed Press, East Lansing, Michigan, 1988

    Google Scholar 

  • Uribe M, Guevara L. Encefalopatia hepatica. In Berenguer J (Ed.) Gastroenterologia y hepatologia, chap. 51, pp. 715–723, Ediciones Doyma. Barcelona, Spain, 1986

    Google Scholar 

  • Uribe M, Marquez MA, Garcia Ramos G, et al. Treatment of chronic portal systemic encephalopathy with vegetable and animal protein diets. A controlled crossover study. Digestive Diseases and Sciences 27: 119–126, 1982

    Google Scholar 

  • Uribe M, Go VLW, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side-effects. Journal of Clinical Gastroenterology 6: 331–335, 1984

    PubMed  CAS  Google Scholar 

  • Vallée BL, Wacker WEC, Bartholomay AF, Hoch FL. Zinc metabolism in hepatic dysfunction: correlation of metabolic patterns with biochemical findings. New England Journal of Medicine 257: 1056–1065, 1957

    Google Scholar 

  • Walker C, Peterson W, Ungar R. Blood ammonia levels in advanced cirrhosis during therapeutic elevation of insulin-glucagon ratio. New England Journal of Medicine 291: 168–171, 1974

    PubMed  CAS  Google Scholar 

  • Walker S, Gotz R, Czygan P, Stiehl A, Kommerell B. Oral keto analogs of branched-chain amino acids on chronic encephalopathy in patients with cirrhosis. A double-blind cross over study. Digestion 24: 105–111, 1982

    PubMed  CAS  Google Scholar 

  • Warhren J, Denis J, Desurmont P, et al. Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study. Hepatology 3: 475–480, 1983

    Google Scholar 

  • Warnes TW, Smith A, Lee F, et al. A controlled trial of colchicine in primary biliary cirrhosis. Journal of Hepatology 5: 1–7, 1987

    PubMed  CAS  Google Scholar 

  • Weber FL. The effect of lactulose on urea metabolism and nitrogen excretion in cirrhotic patients. Gastroenterology 77: 518–523, 1979

    PubMed  Google Scholar 

  • Wiesner RH, Dickson ER, Lindor KD, et al. A controlled clinical trial evaluating cyclosporin in the treatment of primary biliary cirrhosis. A preliminary report. Hepatology 7: 1025, 1987

    Google Scholar 

  • Wiesner RH, Grambsh PM, Lindor KD, et al. Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis. Hepatology 8: 668–676, 1988

    PubMed  CAS  Google Scholar 

  • Wismans PJ, Van Hattum J, Mudde GC, et al. Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. Journal of Hepatology 8: 236–240, 1989

    PubMed  CAS  Google Scholar 

  • Wurtman RJ, Larin F, Mostafarour S. Brain catechol synthesis: control by brain tyrosine concentration. Science 185: 183–186, 1974

    PubMed  CAS  Google Scholar 

  • Yokosuka O, Omata M, Imazeki F, et al. Combination of short-term prednisolone and adenine arabinoside in the treatment of chronic hepatitis B. A controlled study. Gastroenterology 89: 246–251, 1985

    PubMed  CAS  Google Scholar 

  • Yamada T, Ludwig S, Kuhlenkamp J. Direct protection against acetaminophen hepatotoxicity by propylthiouracil: in vivo and vitro studies. Journal of Clinical Investigation 67: 688–695, 1981

    PubMed  CAS  Google Scholar 

  • Yuki T, Israel Y, Thurman RG. The swift increase in alcohol metabolism: inhibition by propylthiouracil. Biochemical Pharmacology 31: 2403–2407, 1982

    PubMed  CAS  Google Scholar 

  • Zarski JP, Arnaud J, Dumolard L, Favier A, Rachail M. Oligoéléments (zinc, cuivre, manganèse) dans la cirrhose alcoolique: influence de l’alcoolisme chronique. Gastroentérologie Clinique et Biologique 9: 664–669, 1985

    PubMed  CAS  Google Scholar 

  • Zieve I. The mechanism of hepatic coma. Hepatology 1: 360–365, 1981

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver Unit, Pontchaillou Hospital, 35033, Rennes Cédex, France

    M. Messner & P. Brissot

Authors
  1. M. Messner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Brissot
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03257491.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Messner, M., Brissot, P. Traditional Management of Liver Disorders. Drugs 40 (Suppl 3), 45–57 (1990). https://doi.org/10.2165/00003495-199000403-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199000403-00005

Keywords

Search

Navigation